Entries by CAPTIS

Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate

The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure The post Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate appeared first on Pharmaceutical Business review.